Nippon Shinyaku on Track to Achieve Targets in Midterm Plan with Sales of Selexipag Above Expectations: President

Nippon Shinyaku President Shigenobu Maekawa Nippon Shinyaku is on track to achieve the targets in its five-year business plan as its pulmonary arterial hypertension (PAH) drug selexipag has gotten off to a stronger than expected start overseas, President Shigenobu Maekawa...read more